Bristol Myers buys Nvidia's latest AI computing system for drug research
BMY•Growing computing demand and efficiency gains
Greg Meyers, the company's chief digital and technology officer, said the investment was driven in part by rapidly growing computing demands as Bristol deploys larger AI models across its research organization. It uses AI in all of its small-molecule and most of its large-molecule programs.
He also said the new system will be more energy efficient.
"When you host these things, you have to pay an electric bill," Meyers said. "Think of it as 10 times more compute capacity per watt spent ... Electricity is not getting cheaper."
Bristol Myers buys Nvidia's latest AI computing system
Bristol Myers Squibb said on Monday it is buying the latest-generation computing system from chip company Nvidia to support its use of artificial intelligence across its drug discovery and development operations.
The drugmaker said it will be the first life sciences company to buy an Nvidia DGX SuperPOD based on its Vera Rubin systems. The chipmaker unveiled its Vera Rubin architecture earlier this year as the successor to its current generation of AI computing systems.
Financial terms of the Bristol Myers investment were not disclosed. It builds on a smaller SuperPOD system the drugmaker bought from Nvidia, which is around two or three generations behind Vera Rubin, BMS executives said in an interview.
AI investment aims to speed drug discovery and development
Pharmaceutical companies are increasingly investing in AI infrastructure to try to identify drug targets faster and improve the odds that experimental drugs succeed in clinical trials.
Robert Plenge, chief research officer at Bristol Myers, said the new capabilities would allow the company to cycle through many more potential drug candidates early in the drug development cycle.
